Sign in to view content

One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO

Mark R. Barakat, MD

Video
Published 2020

Related

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
OCT Angiography (OCTA) and Exudative Age-Related Macular Degeneration (ARMD)
Mark H. Nelson, MD, MBA
Updates from the Field
2017
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019

Category: Age-Related Macular Degeneration

See more